Navidea Biopharmaceuticals (NAVB) Competitors $0.0007 +0.00 (+16.67%) As of 05/1/2025 03:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsTrendsBuy This Stock NAVB vs. BON, UPC, ADTX, VAXX, HSTO, CALA, SCPS, EVLO, CMRA, and GNCAQShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Bon Natural Life (BON), Universe Pharmaceuticals (UPC), Aditxt (ADTX), Vaxxinity (VAXX), Histogen (HSTO), Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Bon Natural Life Universe Pharmaceuticals Aditxt Vaxxinity Histogen Calithera Biosciences Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Bon Natural Life (NYSE:BON) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Which has more risk & volatility, BON or NAVB? Bon Natural Life has a beta of -0.51, suggesting that its share price is 151% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Do insiders & institutionals have more ownership in BON or NAVB? 0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor BON or NAVB? In the previous week, Bon Natural Life had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Bon Natural Life and 0 mentions for Navidea Biopharmaceuticals. Bon Natural Life's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Bon Natural Life Neutral Navidea Biopharmaceuticals Neutral Does the MarketBeat Community believe in BON or NAVB? Bon Natural Life and Navidea Biopharmaceuticals both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformBon Natural LifeN/AN/ANavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes85100.00% Which has higher valuation & earnings, BON or NAVB? Bon Natural Life has higher revenue and earnings than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBon Natural Life$23.84M0.01$400KN/AN/ANavidea Biopharmaceuticals$8.13K8.62-$15.18MN/AN/A Is BON or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Bon Natural LifeN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A SummaryBon Natural Life beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$70,000.00$2.60B$5.53B$18.96BDividend YieldN/A0.75%5.11%4.01%P/E RatioN/A7.7322.5132.87Price / Sales8.6248.76397.6228.03Price / CashN/A15.7538.1817.52Price / BookN/A3.766.734.47Net Income-$15.18M-$65.73M$3.22B$1.02B7 Day PerformanceN/A-0.16%1.38%0.59%1 Month PerformanceN/A-4.58%2.79%-3.54%1 Year PerformanceN/A-12.29%15.41%3.80% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00+16.7%N/A-98.1%$70,000.00$8,126.000.0010Analyst ForecastGap UpBONBon Natural LifeN/A$0.06+2.8%N/A-98.3%$234,000.00$23.84M0.00100Gap UpUPCUniverse PharmaceuticalsN/A$4.14+16.3%N/A-99.6%$178,000.00$26.73M0.00220Gap DownHigh Trading VolumeADTXAditxt0.5956 of 5 stars$2.23-10.8%N/A-100.0%$127,000.00$133,985.000.0060VAXXVaxxinityN/A$0.00-90.0%N/A-87.8%$127,000.00N/A0.0090Gap DownHSTOHistogenN/A$0.03flatN/A-84.0%$124,000.00$19,000.00-0.0120CALACalithera BiosciencesN/A$0.01flatN/AN/A$24,000.00N/A0.0060SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120Options VolumeCMRAComera Life SciencesN/A$0.00flatN/A-99.7%$6,000.00$1.00M0.002Gap DownGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070 Related Companies and Tools Related Companies Bon Natural Life Competitors Universe Pharmaceuticals Competitors Aditxt Competitors Vaxxinity Competitors Histogen Competitors Calithera Biosciences Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAVB Stock Free NAVB Stock Alerts